Literature DB >> 10440687

Differences in mucus and K-ras mutation in relation to phenotypes of tumors of the papilla of vater.

H Matsubayashi1, H Watanabe, T Yamaguchi, Y Ajioka, K Nishikura, H Kijima, T Saito.   

Abstract

BACKGROUND: To investigate their hypothesis that K-ras mutation is correlated with epithelial metaplastic change, the authors classified tumors of the papilla of Vater histologically and according to mucin histochemistry as either intestinal type (complete or incomplete) or pancreaticobiliary type (ordinary or metaplastic) and analyzed the tumors for K-ras mutation during tumorigenesis.
METHODS: Fifty-two tumors of the papilla of Vater (5 adenomas, 24 carcinomas with adenoma component, and 23 carcinomas) obtained from surgical specimens were evaluated. The mucus phenotype was analyzed with MUC1, MUC2, MUC5AC, sialyl Lewis(a) (CA 19-9), HID-AB, and ConA III stainings. K-ras codon 12 mutation was detected by nested polymerase chain reaction (PCR)-restriction fragment length polymorphism and enriched PCR-enzyme-linked minisequence assay.
RESULTS: The presence of adenoma component and intramucosal tumor spreading in the ampulloduodenum was significantly higher in intestinal-type tumors (90%, 27 of 30 tumors, and 100%, 30 of 30 tumors, respectively) than in pancreaticobiliary-type tumors (9%, 2 of 22 tumors, and 23%, 5 of 22 tumors, respectively) (P < 0.0001). MUC2 expression was positive in intestinal-type tumors but not in pancreaticobiliary-type tumors. K-ras mutation rates for incomplete intestinal-type tumors (78%, 7 of 9) and metaplastic pancreaticobiliary-type tumors (64%, 7 of 11), which showed MUC5AC (gastric-type apomucin) expression in cytoplasm, were significantly higher than in complete intestinal-type tumors (33%, 6 of 21) and ordinary pancreaticobiliary-type tumors (18%, 2 of 11) (P = 0.01 and P = 0.03, respectively). In pancreaticobiliary-type tumors, K-ras mutation was more frequently recognized in tumors with ampullopancreatic duct tumor extension (75%, 3 of 4) than in those with ampullobiliary duct extension (0%, 0 of 6) (P = 0.01). Furthermore, sequences of K-ras codon 12 were common in 17 carcinomas with adenoma component that were analyzed for both adenoma and carcinoma.
CONCLUSIONS: Tumors of the papilla of Vater can be classified histologically as either intestinal type or pancreaticobiliary type, and they have different features according to tumor location, association with adenoma, and MUC2 expression. Furthermore, K-ras mutation is supposed to be associated with tumors arising in the area from the ampulloduodenum to the ampullopancreatic duct, with metaplastic mucus occurring in both intestinal and pancreaticobiliary types. Copyright 1999 American Cancer Society.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10440687

Source DB:  PubMed          Journal:  Cancer        ISSN: 0008-543X            Impact factor:   6.860


  21 in total

1.  Prognostic factors for ampullary adenocarcinomas: tumor stage, tumor histology, tumor location, immunohistochemistry and microsatellite instability.

Authors:  Fausto Sessa; Daniela Furlan; Clementina Zampatti; Ileana Carnevali; Francesca Franzi; Carlo Capella
Journal:  Virchows Arch       Date:  2007-07-26       Impact factor: 4.064

2.  Genetic alterations in Japanese extrahepatic biliary tract cancer.

Authors:  Rei Noguchi; Kiyoshi Yamaguchi; Tsuneo Ikenoue; Yumi Terakado; Yasunori Ohta; Naohide Yamashita; Osamu Kainuma; Sana Yokoi; Yoshiaki Maru; Hiroki Nagase; Yoichi Furukawa
Journal:  Oncol Lett       Date:  2017-05-22       Impact factor: 2.967

3.  Histological evaluation of preoperative biopsies from ampulla vateri.

Authors:  Gábor Elek; Sándor Gyôri; Bernadett Tóth; Akos Pap
Journal:  Pathol Oncol Res       Date:  2003-04-18       Impact factor: 3.201

4.  Clinicopathological Study of Carcinoma of the Ampulla of Vater with Special Reference to MUC1, MUC2 and MUC5AC Expression.

Authors:  Maithili Mandar Kulkarni; Siddhi Gaurish Sinai Khandeparkar; Avinash R Joshi; Aniket Kakade; Lokesh Fegade; Ketan Narkhede
Journal:  J Clin Diagn Res       Date:  2017-05-01

5.  COX-2 expression of ampullary carcinoma: correlation with different histotypes and clinicopathological parameters.

Authors:  Giuseppe Perrone; Daniele Santini; Mariagiovanna Zagami; Bruno Vincenzi; Alfio Verzì; Sergio Morini; Domenico Borzomati; Roberto Coppola; Armando Antinori; Paolo Magistrelli; Giuseppe Tonini; Carla Rabitti
Journal:  Virchows Arch       Date:  2006-08-12       Impact factor: 4.064

6.  K-ras mutation in the major duodenal papilla and gastric and colonic mucosa in patients with autoimmune pancreatitis.

Authors:  Terumi Kamisawa; Shin-Ichirou Horiguchi; Yukiko Hayashi; Xiaoqing Yun; Toshikazu Yamaguchi; Koji Tsuruta; Tsuneo Sasaki
Journal:  J Gastroenterol       Date:  2010-02-16       Impact factor: 7.527

Review 7.  [Pathogenesis and histomorphology of ampullary carcinomas and their precursor lesions. Review and individual findings].

Authors:  H-P Fischer; H Zhou
Journal:  Pathologe       Date:  2003-04-09       Impact factor: 1.011

8.  Immunophenotyping and oncogene amplifications in tumors of the papilla of Vater.

Authors:  Daniel Baumhoer; Inti Zlobec; Luigi Tornillo; Wolfgang Dietmaier; Peter H Wuensch; Arndt Hartmann; Fausto Sessa; Petra Ruemmele; Luigi M Terracciano
Journal:  Virchows Arch       Date:  2008-10-21       Impact factor: 4.064

Review 9.  Endoscopic ultrasonography guided-fine needle aspiration for the diagnosis of solid pancreaticobiliary lesions: Clinical aspects to improve the diagnosis.

Authors:  Hiroyuki Matsubayashi; Toru Matsui; Yohei Yabuuchi; Kenichiro Imai; Masaki Tanaka; Naomi Kakushima; Keiko Sasaki; Hiroyuki Ono
Journal:  World J Gastroenterol       Date:  2016-01-14       Impact factor: 5.742

10.  Differentiation markers in pancreatic head adenocarcinomas: MUC1 and MUC4 expression indicates poor prognosis in pancreatobiliary differentiated tumours.

Authors:  Arne Westgaard; Aasa R Schjølberg; Milada Cvancarova; Tor J Eide; Ole Petter F Clausen; Ivar P Gladhaug
Journal:  Histopathology       Date:  2009-02       Impact factor: 5.087

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.